A) Geodon B) Prolixin C) Zyprexa D) Risperdal
A) Zyprexa B) Clozaril C) Invega D) Abilify
A) Invega B) Seroquel C) Zyprexa D) Abilify
A) Zyprexa B) Seroquel C) Abilify D) Risperdal
A) Geodon B) Abilify C) Risperdal D) Seroquel
A) Clozapine B) Olanzapine C) Ziprasidone D) Quetiapine
A) Ziprasidone B) Risperidone C) Aripriprazole D) Paliperidone
A) Clozaril B) Seroquel C) Risperdal D) Geodon
A) Ziprasidone B) Aripiprazole C) Clozapine D) Paliperidone
A) Olazapine B) Quetiapine C) Risperdone D) Paliperidone
A) Risperidone and Paliperidone B) Clozapine and Risperadone C) Clozapine and Aripiprazole D) Aripiprazole and Paliperidone
A) 1-3 B) 4-5 C) 2-5 D) 1
A) 18 B) 6 C) 12 D) 24
A) FALSE B) TRUE
A) Develop more adaptive coping skills B) Minimize side effects of medication C) Prevent relapse into another psychotic episode D) Foster patients' medication compliance
A) directly after discontinuation of medication B) several weeks after discontinuation of medication C) six months after discontinuation of medication D) one year after discontinuation of medication
A) Clozaril B) Thorazine C) Symmetrel D) Artane
A) weight gain more common B) tardive dyskinesia more common C) enhanced efficacy in treatment-resistant patients D) increased effectiveness for positive, negative, and disorganized symptoms
A) Haloperiodol B) Clozapine C) Prochlorperazine D) Risperidone
A) Stimulants B) Alcohol C) Anxiolitics D) Anticonvulsants
A) Halperiodol B) Merperidine C) Beta blockers D) Alcohol
A) Anticonvulsants B) Antacids C) Nicotine D) Beta blockers
A) Alcohol B) Beta blockers C) Tricyclic antidepressants D) SSRIs
A) FALSE B) TRUE
A) Male gender B) Drug holidays C) Tobacco use D) Alcohol use
A) TRUE B) FALSE
A) All antipsychotic drugs but Clozapine present a significant risk for the development of tardive dyskinesia. B) The more frequent the dose of the antipsychotic medication, the greater the risk for the development of tardive dyskinesia. C) Classic antipsychotic medications present less risk for the development of tardive dyskinesia than atypical antipsychotic medications. D) High potency antipsychotic drugs present greater risk for the development of tardive dyskinesia.
A) Akathesia B) Ataxia C) Akinesia D) Acute dystonia
A) Neuroleptic Malignant Syndrome B) Gynecomastia C) Postural hypotension D) Agranulocytosis
A) FALSE B) TRUE
A) FALSE B) TRUE
A) agonize the normal dopamine-mediated inhibition of prolactin release. B) block D2 receptors in the pituitary gland and decrease prolactin secretion. C) block D2 receptors in the pituitary gland and inhibit prolactin secretion. D) antagonize the normal dopamine-mediated inhibition of prolactin release.
A) molecular structure B) receptor binding and DA turnover C) neuroendocrine changes D) hungry hungry hippos
A) Butyrophenones B) Sleepykoaladones C) Thioxanthenenes D) Phenothiazines
A) Potent; low; lower B) Potent; low; higher C) Weak; high; higher D) Weak; high; lower
A) Hallucinations B) Anhedonia C) Delusions D) Formal thought disorder
A) Neurological disorders B) All of the above C) Metabolic disorders D) Autoimmune diseases E) Endocrine disorders
A) All of the above B) Alcohol C) Stimulants D) Hallucinogens E) Opioids
A) FALSE B) TRUE
A) negative symptoms of Schizophrenia. B) positive symptoms of Schizophrenia. C) disorganized symptoms of Schizophrenia. D) All of the above.
A) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine release. B) blocking post-synaptic dopamine receptors and/or inhibiting dopamine reuptake. C) blocking post-synaptic dopamine receptors and/or inhibiting dopamine release. D) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine reuptake.
A) the drug increases the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine. B) the drug reduces the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine. C) the drug increases the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine. D) the drug reduces the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine.
A) increased rates of firing B) increased rates of synthesis C) increased release of dopamine D) increased tap dancing
A) piperazines B) thioxanthenes C) aliphatics D) piperideines
A) all of the above B) menstrual irregularity C) galactorrhea D) genecomastia
A) Inapsine (droperiodol) B) Benadryl (diphenhydramine) C) Symmetrel (amantadine) D) Cogentin (benztropine) E) Artane (trihexphenidyl)
A) TRUE B) FALSE
A) comparative lack of EPS B) polypharmacy C) superior impact on positive symptoms D) actual impact at the biological level
A) Clozaril B) Invega C) Abilify D) Haldol
A) Clorazil B) Seroquel C) Risperdal D) Geodon |